Theophylline choline 600 mg was given as a single oral dose to nine patients in chronic left ventricular failure due to myocardial dysfunction. Cardiac output, left ventricular filling pressure (LVFP) and right atrial pressure (RAP) were measured with a pulmonary artery thermodilution catheter for the following 3 hr. Continuous recordings of cardiac rhythm were made throughout the study. Mean cardiac index increased from 1F75 (±0-14 s.e. mean) to 2-04 (+0 11) 1/min/m2 (P< 0-02), mean LVFP fell from 27 (±2-4) to 22 (±1-5) mmHg (P<0-01), mean RAP fell from 5 (±1-3) to 3 (±2 0) mmHg (P < 0 05) and mean systemic arterial pressure rose from 80 (±3) to 86 (±3-5) mmHg (P < 0 05). There were no significant changes in heart rate or systemic vascular resistance; thus the increase in cardiac output was probably due to a positive inotropic effect. Side effects were seen in two patients, both of whom proved to have toxic plasma theophylline concentrations. This study demonstrated a beneficial acute haemodynamic effect of oral theophylline in chronic cardiac failure.
Introduction
In patients with severe chronic heart failure resistant to diuretics there is a need for additional oral agents capable of improving cardiac haemodynamics. Such agents include hydralazine which reduces afterload (Fitchet et al., 1979) , isosorbide dinitrate which reduces preload (Williams et al., 1977) , and salbutamol which may increase cardiac output by a mixture of afterload reduction and positive inotropism (Sharma and Goodwin, 1978) .
Intravenous infusions of theoptiylline (and its derivative aminophylline) are known to increase cardiac output in patients in heart failure (Howarth, McMichael and Sharpey-Schafer, 1947; Parker, Kelly and West, 1966) . This is predominantly through a positive inotropic effect (Murphy, Schreiner and Yu, 1968) , although a peripheral vasodilator action has also been suggested (Parker et al., 1966) . As there are now long-acting oral preparations of theophylline, this drug may be a useful addition to the agents already in use in the treatment of refractory chronic heart failure. However, there are no reported studies on the haemodynamic effects of theophylline or aminophylline given orally in chronic left ventricular failure.
The aim of this study was to assess the haemodynamic effects of a single, rapidly absorbed oral dose of theophylline and to identify possible side effects in relation to plasma theophylline concentrations.
Patients and methods
Nine men were studied (Table 1) . Their heart failure was due to myocardial dysfunction rather than valvular pathology, as determined by cardiac catheterization or echocardiography. The patients were all refractory to diuretics and had been admitted for stabilization of heart failure. The insertion of a pulmonary artery catheter formed part of their routine management. All CI.E *°u)
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The patients were specifically questioned at 30-min intervals about nausea, tremor, headaches and chest pain.
Blood samples were taken immediately before the drug was given and at 30-min intervals thereafter for 3 hr. The samples were centrifuged immediately and the plasma frozen at -20°C for later analysis. Plasma theophylline concentrations were measured by a homogeneous enzyme immunoassay (EMITSyva, St Ives House, Maidenhead, Berkshire, England). In asthmatic patients the therapeutic range is 10-20 ,ug/ml (Mitenko and Ogilvie, 1973; Nicholson and Chick, 1973) .
All studies were performed following an overnight fast, the patients receiving no medication on the morning of the study.
Haemodynamic measurements
A triple lumen thermister-tipped flotation balloon catheter was introduced through a subclavian vein and passed under fluoroscopic control into the pulmonary artery. Right atrial pressure (RAP), mean pulmonary artery wedge pressure (MPAWP) and pulmonary artery systolic and diastolic pressures were measured using Bell and Howell transducers and displayed on a Roche 144 monitor. The zero point was set at the sternal angle with the patient positioned at 45°. Cardiac output (CO) was measured by thermodilution (Ganz and Swan, 1972) . Measurements were made in triplicate and the mean was calculated. Systemic arterial pressure (SAP) was measured with an indwelling radial artery catheter in two patients and sphygmomanometrically in the remainder. Heart rate was counted from the ECG monitor over a period of one min at the start of each set of observations.
The study consisted of a 30-min control period followed by a 3-hr period in which the effects of the drug were observed. (Jenkins, Bradley and Branthwaite, 1970) .
The following formulae were also used: cardiac index (CI) I/min/m2 = (CO (Fig. 1, Table 2 ).
The mean control Cl was 1-75 (±0-14 s.e. mean) 1/min/m2 and it rose following the administration of theophylline to a maximum of 2-04 (±0-1 1)1/min/m2 at 180 min (P < 0-02). The increase in CI was seen in 7 of the 9 patients, the maximum rises ranging from 9 % to 40 %. 25 Jg/ml. The arrhythmia occurred one hour after this peak was reached, at which time plasma theophylline concentration was 14-5 ,[g/ml.
Plasma theophylline concentrations were measured in all nine patients. Absorption of theophylline was variable; the peak plasma concentrations were reached between 30 and 120 min following administration and ranged from 8 to 25 [±g/ml (average 14 (g/ml at one hour). Side effects were only seen in the two patients who had plasma theophylline concentrations exceeding 19 tg/ml. There were no correlations between peak plasma theophylline concentrations and the maximum changes in CI or LVFP.
Discussion
Intravenous theophylline and its derivatives were used for many years for the treatment of acute pulmonary oedema but the drug fell out of use following the recognition of serious side effects, in particular tachyarrhythmia and vomiting. These side effects were probably due to drug overdose, as theophylline clearance is reduced in heart failure (Powell et al., 1978) ; when plasma theophylline concentrations are kept within the therapeutic range of 10-20 (g/ml side effects are rarely encountered (Mitenko and Ogilvie, 1973; Nicholson and Chick, 1973) . The introduction of oral slow release preparations of theophylline and aminophylline has been an important development as they avoid the peaks and troughs of plasma theophylline that were seen with the former preparations (Jones, 1979 (Marcus et al., 1972) and intravenous infusions of aminophylline exert a positive inotropic effect in patients undergoing cardiac catheterization for valvular disease (Murphy et al., 1968) . As might be expected, CO is increased in those patients whose cardiac failure is due to myocardial rather than valvular pathology (Howarth et al., 1947; Parker et al., 1966; Murphy et al., 1968) . The increase in CO and fall in LVFP in the present study can best be explained by a positive inotropic effect. Parker et al. (1966) suggested that peripheral vasodilatation may have a contributory effect on increasing cardiac output, but that mechanism cannot be invoked in this study as SVR did not fall. Howarth et al. (1947) examined the possibility that the increase in cardiac output may be due to venodilatation; they produced comparable reductions in RAP by congesting cuffs on the thighs and intravenous infusions of aminophylline, and found that the increase in cardiac output resulting from the latter was much greater. They concluded that aminophylline increases cardiac output by 'a direct stimulating action on the heart' rather than by venodilatation.
Two hypotheses, not mutually exclusive, have been proposed to explain the effect of theophylline on myocardial contractility. The first is by enhancing the calcium permeability of the sarcolemma (Scholz, 1971 a,b) , and the second by inhibition of phosphodiesterase, leading to an accumulation of cAMP intracellularly (Skelton, Levey and Epstein, 1970) . The site of action of theophylline is probably on the sarcolemma rather than intracellularly (Bellemann and Scholz, 1974 and Scholz, , 1975 .
Side effects were only seen in two patients who had toxic plasma theophylline concentrations. It is not clear whether the development of an arrhythmia in one patient was due to theophylline administration, as this patient had had the arrhythmia before administration of the drug. In any case, a history of tachyarrhythmia may constitute a contra-indication to the administration of theophylline.
This study has shown that a rapidly absorbed oral theophylline preparation exerts a beneficial acute haemodynamic effect in chronic heart failure. Further studies will concentrate on a slow-release preparation in an attempt to determine whether the beneficial effects persist, and the ease with which plasma theophylline concentrations can be kept within the therapeutic range.
